Arbor Biotechnologies discovers and develops next-generation genetic medicines using a machine learning/AI-driven discovery platform that mines a proprietary protein database. The company has built what it describes as the most extensive toolbox of wholly owned CRISPR genomic editors in the industry. Using its platform, Arbor discovers, screens, and engineers novel editing enzymes and effectors that can be tailored to target the root causes of genetic diseases. Arbor has partnered with Vertex Pharmaceuticals on several gene editing and ex vivo cell therapy programs. The company plans to use new financing to advance lead liver and CNS programs into the clinic, progress a pipeline of precision editing therapeutics (including CRISPR nucleases and transposases), and continue investing in its discovery engine. Founded in 2016 and based in Cambridge, Mass., Arbor has raised over $300 million to date.

Total raised

$215M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2021